Dysregulation of miR-146a-5p/RHOJ and miR-146b-5p/RHOJ axis in the plasma and ECFCs of CAD patients could be used as biomarkers or therapeutic targets for CAD and other angiogenesis-related diseases [22]. The gene discussed is RHOJ; the disease is coronary artery disorder.